ClinicalTrials.gg
RecruitingNCT07846683AMETRINE-SCUpdated Oct 26, 2026

A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Afimkibart and Placebo in Moderately to Severely Active Ulcerative Colitis, sponsored by Hoffmann-La Roche. Recruiting at 1 site in United States. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche — 4 open to participants now, 6 under way, 4 of them phase 3. Colitis, Ulcerative · Hoffmann-La Roche.

Planned enrollment
8th of 24
350 · median 169
Started
2026
with 2 others
Phase 3
10 of 24
2 open now
Registered
24th of 24
by date

Among the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 10 in phase 3, and was the 24th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).

03

Conditions studied

  • Moderately to Severely Active Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of UC.
  • Moderately to severely active UC assessed by modified Mayo Score (mMS).
  • Bodyweight >= 40 kilogram (kg).
  • Up to date with colorectal cancer (CRC) screening performed according to local standards.
  • Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced UC therapy.
  • Females of must meet protocol criteria for requirements.

Exclusion criteria

Exclusion Criteria:

  • Currently known complications of UC (e.g. fulminant colitis, toxic megacolon).
  • Current diagnosis of Crohn's disease (CD) or indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis.
  • Presence of an ostomy or ileoanal pouch.
  • Current diagnosis or suspicion of primary sclerosing cholangitis.
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study.
  • Past or current evidence of definite low-grade or high-grade colonic dysplasia or adenomas or neoplasia not completely removed.
  • History of within 5 years, with the exception of malignancies adequately treated with resection for non- basal cell or squamous cell cancer or in situ cervical cancer.
  • Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), (HIV), (HBV), (HCV).
  • Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB.
  • Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Afimkibart

    Participants will receive afimkibart administered as subcutaneous (SC) injection.

    Drug: Afimkibart

  • Placebo comparator
    Placebo

    Participants will receive placebo adminsitered as SC injection.

    Drug: Placebo

Interventions

  • Afimkibart will be administered as SC injection.

    Also known as: PF-06480605, RVT-3101, RO7790121

  • DrugPlacebo

    Placebo will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission

    Time frame: At Week 12

Secondary outcomes

  1. Change From Baseline in Stool Frequency Subscore (SFS)

    The Stool Frequency Subscore (SFS) is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal)

    Time frame: From Baseline up to Week 12

  2. Change From Baseline in Rectal Bleeding Subscore (RBS)

    The Rectal Bleeding Subscore (RBS) is measured on a scale from 0 (no blood seen) to 3 (blood alone passed)

    Time frame: From Baseline up to Week 12

  3. Percentage of Participants With Symptomatic Response

    Time frame: At Week 4

  4. Percentage of Participants With Endoscopic Improvement

    Time frame: At Week 12 and Week 24

  5. Percentage of Participants With Endoscopic Remission

    Time frame: At Week 12 and Week 24

  6. Percentage of Participants With Clinical Response

    Time frame: At Week 12

  7. Percentage of Participants With Histologic-Endoscopic Mucosal Improvement

    Time frame: At Week 12 and Week 24

  8. Percentage of Participants With Clinical Remission

    Time frame: At Week 24

  9. Percentage of Participants With Maintenance of Remission

    Time frame: At Week 12 and Week 24

  10. Percentage of Participants With Histologic Improvement

    Time frame: At Week 24

  11. Change From Baseline in Bowel Urgency

    Bowel urgency will be assessed using two self-reported items over the past 24 hours: presence of bowel urgency (Yes/No) and severity on an 11-point numerical rating scale from 0 (no urgency) to 10 (worst possible urgency)

    Time frame: From Baseline through Week 12 and Week 24

  12. Change From Baseline in Abdominal Pain

    Abdominal pain will be assessed using two self-reported items over the past 24 hours: presence of abdominal pain (Yes/No) and severity on an 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain)

    Time frame: From Baseline through Week 12 and Week 24

  13. Change From Baseline in Fatigue

    Change in fatigue will be assessed by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. FACIT-Fatigue is a 13-item self-reported assessment of the level and impact of fatigue. The overall FACIT-Fatigue score ranges between 0 and 52, with higher scores associated with better quality of life concerns related to fatigue

    Time frame: From Baseline through Week 12 and Week 24

  14. Change From Baseline in Health-Related Quality of Life

    Change in health-related quality of life will be assessed by Inflammatory Bowel Disease Questionnaire (IBDQ) score. IBDQ is a 32-item self-reported assessment of health-related quality of life in participants with inflammatory bowel disease. The overall IBDQ score ranges from 32 to 224, with higher scores associated with better health-related quality of life

    Time frame: From Baseline through Week 12 and Week 24

  15. Change From Baseline in Overall UC Symptoms

    Change in overall UC symptoms will be assessed by Patient Global Impression of Change (PGIC). PGIC measures overall change in ulcerative colitis symptoms from "Much better" to "Much worse"

    Time frame: Baseline, Week 2, Week 12 and Week 24

  16. Change From Baseline in Overall Severity in UC Symptoms

    Change in overall severity of UC symptoms will be assessed by Patient Global Impression of Severity (PGIS). PGIS measures severity of ulcerative colitis symptoms from "None" to "Very severe"

    Time frame: Baseline, Week 2, Week 12 and Week 24

  17. Incidence and Severity of Adverse Events (AEs)

    Time frame: From Baseline up to approximately 42 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 18 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 29, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in United States
Show site
  • Gastro One · Cordova, United States
Oct 26, 2026
Title
A Study to Assess the Efficacy and Safety of Afimkibart forSubcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
Oct 26, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Gastro One · Cordova, United States
    Title A Study to Assess the Efficacy and Safety of Afimkibart forSubcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846683
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
May 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Reference Study ID Number: CA46523 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion